These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33393047)

  • 21. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
    Fietkau R; Grützmann R; Wittel UA; Croner RS; Jacobasch L; Neumann UP; Reinacher-Schick A; Imhoff D; Boeck S; Keilholz L; Oettle H; Hohenberger WM; Golcher H; Bechstein WO; Uhl W; Pirkl A; Adler W; Semrau S; Rutzner S; Ghadimi M; Lubgan D
    Strahlenther Onkol; 2021 Jan; 197(1):8-18. PubMed ID: 32914237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
    Temraz S; Nassar F; Hammoud MS; Mukherji D; O'Reilly EM; Dbouk H; Farhat F; Charafeddine M; Faraj W; Khalifeh MJ; Abou-Alfa GK; Shamseddine A
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):735-742. PubMed ID: 35362216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
    Choi YH; Lee SH; You MS; Shin BS; Paik WH; Ryu JK; Kim YT; Kwon W; Jang JY; Kim SW
    Gut Liver; 2021 Mar; 15(2):315-323. PubMed ID: 32235008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.
    Acuna-Villaorduna A; Shankar V; Wysota M; Jirgal A; Kabarriti R; Bellemare S; Goldman I; Kaubisch A; Aparo S; Goel S; Chuy J
    Cancer Control; 2022; 29():10732748221134411. PubMed ID: 36221952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
    Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
    PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
    Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
    Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
    Park SJ; Kim JH; Joo I; Lee KB; Han JK
    Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN; Romero-Hernandez F; Calthorpe L; Wang JJ; Kim SS; Corvera CU; Hirose K; Kirkwood KS; Hirose R; Maker AV; Alseidi AA; Adam MA; Kim GE; Tempero MA; Ko AH; Nakakura EK
    Ann Surg Oncol; 2024 Sep; 31(9):6147-6156. PubMed ID: 38879670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
    Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS
    JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.
    Botta GP; Huynh TR; Spierling-Bagsic SR; Agelidis A; Schaffer R; Lin R; Sigal D
    Cancer Med; 2023 Apr; 12(7):7713-7723. PubMed ID: 36478411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
    Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?
    Garnier J; Robin F; Ewald J; Marchese U; Bergeat D; Boudjema K; Delpero JR; Sulpice L; Turrini O
    Ann Surg Oncol; 2021 Aug; 28(8):4625-4634. PubMed ID: 33462718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
    Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma.
    Medrano J; Garnier J; Ewald J; Marchese U; Gilabert M; Launay S; Poizat F; Giovannini M; Delpero JR; Turrini O
    Pancreatology; 2020 Mar; 20(2):223-228. PubMed ID: 31839458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.